Catalog No.
FHC98822
Species reactivity
Human
Host species
Human
Isotype
IgG2, kappa
Clonality
Monoclonal
Conjugation
PE
Target
ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4, Gut homing receptor beta subunit, Integrin beta-7, ITGB7, α4β7
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
P13612 & P26010
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
SAA0020
A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease., PMID:40512051
Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti-integrin therapy., PMID:40509637
The role of gut leakage and immune cell miss-homing on gut dysbiosis-induced lung inflammation in a DSS mice model., PMID:40435188
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study., PMID:40367195
Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring., PMID:40349212
Pro-inflammatory macrophages contribute to developing comorbid anxiety-like behaviors through gastrointestinal vagal afferent signaling in experimental colitis mice., PMID:40348137
NK cell activation and CD4 T cell α4β7 expression are associated with susceptibility to HIV-1., PMID:40338667
Gut-directed therapeutics in inflammatory bowel disease., PMID:40305008
Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials., PMID:40301737
Identification of S100A9 as a target for diagnosis and treatment of Crohn's Disease after Vedolizumab treatment failure., PMID:40280281
CD37 regulates the self-renewal of leukemic stem cells via integrin-mediated signaling in acute myeloid leukemia., PMID:40250439
Mucosal-associated invariant T (MAIT) cell responses in Salmonella enterica serovar Typhi strain Ty21a oral vaccine recipients., PMID:40224569
The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab., PMID:40182846
Comments on "Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease"., PMID:40158741
Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis., PMID:40138118
In vivo investigation of PEDV transmission via nasal infection: mechanisms of CD4+ T-cell-mediated intestinal infection., PMID:40094365
Biologics in the management of pediatric inflammatory bowel disease: When and what to choose., PMID:40059900
A screening system to determine the effect of bacterial metabolites on MAdCAM-1 expression by transformed endothelial sinusoidal cells., PMID:40058956
An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial., PMID:40043138
A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses., PMID:40006680
High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi Arabia., PMID:40002872
Risk factors and clinical characteristics of Clostridium difficile colonization and infection in patients with inflammatory bowel disease exposed to Vedolizumab: a multicenter retrospective study., PMID:39975482
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity., PMID:39933899
IL-21 and anti-α4β7 dual therapy during ART promotes immunological and microbiome responses in SIV-infected macaques., PMID:39903521
Increases in the susceptibility of human endometrial CD4+ T cells to HIV-1 infection post-menopause are not dependent on greater viral receptor expression frequency., PMID:39872519
Achievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis., PMID:39832030
Anti-PD1-/PDL1-induced chronic intestinal pseudo-obstruction: three cases treated with vedolizumab after corticosteroid failure with mixed results., PMID:39751892
[Application of advanced treatment in chronic inflammatory bowel diseases]., PMID:39747696
Pre-Human Immunodeficiency Virus (HIV) α4β7hi CD4+ T Cells and HIV Risk Among Heterosexual Individuals in Africa., PMID:39720913
Case report: Vedolizumab in Oral Crohn's disease: the downsides of a gut-specific therapy for a multi-site disease., PMID:39697207
Associations Between Polymorphisms of Genes Related to Vitamin D Pathway and the Response to Vedolizumab and Ustekinumab in Inflammatory Bowel Disease., PMID:39685734
Vagal innervation limits brain injury by inhibiting gut-selective integrin-mediated intestinal immunocyte migration in intracerebral hemorrhage., PMID:39659582
Targeting mucosal healing in Crohn's disease: efficacy of novel pathways and therapeutic targets., PMID:39611536
Effect of Integrin Blockade on Experimental Spondyloarthritis., PMID:39595563
Expression of IL-7RαlowCX3CR1+ CD8+ T Cells and α4β7 Integrin Tagged T Cells Related to Mucosal Immunity in Children with Inflammatory Bowel Disease., PMID:39563840
Cell Membrane-Coated Nanotherapeutics for the Targeted Treatment of Acute and Chronic Colitis., PMID:39512421
Immune-mediated colitis after immune checkpoint inhibitor therapy., PMID:39477757
Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs., PMID:39474328
Differential expression of HIV target cells CCR5 and α4β7 in tissue resident memory CD4 T cells in endocervix during the menstrual cycle of HIV seronegative women., PMID:39386203
A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease., PMID:39371119
Association Between Vedolizumab Treatment and Arthritis/Arthralgia in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis., PMID:39348571
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab., PMID:39343860
Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease., PMID:39343250
Expression of integrin α4β1 and α4β7 on B cells correlates with autoimmune responses in Graves' disease., PMID:39317053
Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases., PMID:39308999
CCR2 cooperativity promotes hematopoietic stem cell homing to the bone marrow., PMID:39292787
Corticosteroid-dependent immune checkpoint inhibitor-induced enterocolitis treated with vedolizumab: a case report., PMID:39279935
Changes in monocyte subsets in volunteers who received an oral wild-type Salmonella Typhi challenge and reached typhoid diagnosis criteria., PMID:39263222
Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report., PMID:39205502
Protocol for in vitro generating innate lymphoid cells from mouse α4β7+ lymphoid progenitors., PMID:39180747
For research use only. Not for human or drug use.
